MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

PTC Therapeutics Company Profile (NASDAQ:PTCT)

Consensus Ratings for PTC Therapeutics (NASDAQ:PTCT) (?)
Ratings Breakdown: 8 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $39.70 (496.10% upside)

Analysts' Ratings History for PTC Therapeutics (NASDAQ:PTCT)
Show:
DateFirmActionRatingPrice TargetActions
5/6/2016Credit SuisseReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Jefferies GroupReiterated RatingHold$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/18/2016RBC CapitalReiterated RatingSector Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016OppenheimerReiterated RatingBuy$39.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2016Cowen and CompanyReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/23/2016WedbushReiterated RatingNeutral$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016BarclaysBoost Price TargetOverweight$40.00 -> $100.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Bank of AmericaDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Citigroup Inc.DowngradeBuy -> Neutral$90.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$81.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2015Roth CapitalReiterated RatingHold$63.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/17/2015Deutsche BankReiterated RatingBuy$115.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for PTC Therapeutics (NASDAQ:PTCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
5/5/2016Q116($1.26)($1.22)$13.74 million$18.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($1.25)($1.50)$13.04 million$12.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($1.15)($1.27)$9.88 million$9.78 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($1.20)($1.14)$7.73 million$6.77 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/4/2015Q115($1.20)($1.15)$2.97 million$7.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.83)($0.84)$7.99 million$12.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($0.90)($0.93)$1.76 million$1.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.75)($0.86)$1.71 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014($0.46)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q413($0.57)($0.75)$6.15 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.29)($0.19)$7.20 million$16.29 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for PTC Therapeutics (NASDAQ:PTCT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($1.52)($1.00)($1.28)
Q2 20163($1.48)($0.90)($1.28)
Q3 20163($1.37)($0.90)($1.16)
Q4 20163($1.29)($0.50)($0.98)
(Data provided by Zacks Investment Research)
Dividend History for PTC Therapeutics (NASDAQ:PTCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for PTC Therapeutics (NASDAQ:PTCT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/3/2016Mark RotheraInsiderBuy2,000$6.23$12,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015David P SouthwellDirectorSell23,604$47.52$1,121,662.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015Allan Steven JacobsonDirectorSell5,000$50.13$250,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Stuart Walter PeltzCEOSell100,000$54.49$5,449,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Mark Elliott BouldingVPSell56,849$55.04$3,128,968.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Richard AldrichDirectorSell7,000$55.66$389,620.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Stuart Walter PeltzCEOSell73,700$54.91$4,046,867.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Shane William Charles KovacsCFOSell82,491$55.41$4,570,826.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015Neil Gregory AlmsteadEVPSell9,511$68.65$652,930.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015David P SouthwellDirectorSell2,317$69.04$159,965.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Stuart Walter PeltzCEOSell47,200$69.14$3,263,408.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Mark Elliott BouldingVPSell21,142$68.12$1,440,193.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2015Allan Steven JacobsonDirectorSell16,616$76.00$1,262,816.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Mark RotheraInsiderSell10,700$76.64$820,048.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Michael L KrandaDirectorSell2,500$72.81$182,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Robert J SpiegelInsiderSell1,030$75.10$77,353.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Neil Gregory AlmsteadEVPSell79$70.71$5,586.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Stuart Walter PeltzCEOSell47,201$70.74$3,338,998.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2015Mark RotheraInsiderSell35,000$68.01$2,380,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/24/2015Mark RotheraInsiderSell1,000$67.70$67,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/23/2015Mark RotheraInsiderSell23,000$65.40$1,504,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Neil Gregory AlmsteadEVPSell26,096$60.26$1,572,544.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Mark RotheraInsiderSell3,000$60.02$180,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Mark RotheraInsiderSell2,300$58.67$134,941.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2015Claudia De Oliveira Ri HirawatPresidentSell2,149$57.19$122,901.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Mark RotheraInsiderSell9,700$58.04$562,988.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$55.24$120,036.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2014Claudia De Oliveira Ri HirawatPresidentSell2,173$39.78$86,441.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2014Claudia De Oliveira Ri HirawatPresidentSell45,661$36.15$1,650,645.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2014Claudia De Oliveira Ri HirawatPresidentSell43,489$36.18$1,573,432.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Stuart Walter PeltzCEOSell41,501$42.65$1,770,017.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Mark RotheraInsiderSell16,000$44.63$714,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2014Allan Steven JacobsonDirectorSell2,000$40.16$80,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2014Mark RotheraInsiderSell8,000$36.24$289,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Shane William Charles KovacsCFOSell1,650$14.74$24,321.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/24/2014Stuart Walter PeltzCEOSell25,487$29.86$761,041.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Claudia De Oliveira Ri HirawatPresidentSell15,320$29.61$453,625.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014David SouthwellDirectorSell2,317$30.93$71,664.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Mark Elliott BouldingVPSell10,049$30.96$311,117.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2014Neil Gregory AlmsteadVPSell10,859$31.91$346,510.69View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2014Allan Steven JacobsonDirectorSell7,616$31.18$237,466.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Michael KrandaDirectorSell1,186$31.02$36,789.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2014Robert SpiegelInsiderSell1,186$31.75$37,655.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Stuart Walter PeltzCEOSell27,414$29.91$819,952.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Hbm Healthcare Investments (Camajor shareholderSell66,667$19.08$1,272,006.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Adam KoppelDirectorBuy1,250,000$15.00$18,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Hbm Healthcare Investments (CaMajor ShareholderBuy666,676$15.00$10,000,140.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Mark RotheraInsiderBuy25,000$15.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for PTC Therapeutics (NASDAQ:PTCT)
DateHeadline
06/25/16 09:42 AMPTC Therapeutics Inc. (PTCT) Jumps 6.06% on June 23 - Equities.com
06/24/16 06:01 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 06:01 PMPtc Therapeutics Incorporated (NASDAQ:PTCT) Sellers Increased By 7.49% Their Shorts - Engelwood Daily
06/22/16 05:56 PMPTC Therapeutics (NASDAQ:PTCT) Analyst Rating Consensus - TheFounders Daily
06/22/16 05:56 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Momentum Hits Weakness - CML News
06/15/16 10:32 AMSnapshot of Recent Traded Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Tenet Healthcare Corporation (NYSE:THC) - Street Updates
06/14/16 10:45 AMBiotechnology Equities Technical Briefing -- PTC Therapeutics, Biogen, Progenics Pharma, and VIVUS
06/13/16 03:32 PMPTC THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/13/16 08:56 AMAnalytical Report of the Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT), Aegerion Pharmaceuticals, Inc. (NASDAQ ... - Beacon Chronicle
06/13/16 07:19 AMPTC Therapeutics Appoints Dawn Svoronos to Board of Directors - [at noodls] - SOUTH PLAINFIELD, N.J., June 13, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently ...
06/12/16 05:53 PMStock is down at $7.33 New Analyses from Phase 3 Study 009 of…
06/12/16 05:53 PMPTC Therapeutics (PTCT) Announces Presentation of New Analysis from Translarna Phase 3 in CF
06/11/16 06:09 PMKeep an eye on Analyst Actions: Agilent Technologies, Inc. (NYSE:A) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/11/16 08:51 AMPTC Therapeutics (PTCT) Announces Presentation of New Analysis from Translarna Phase 3 in CF - StreetInsider.com
06/10/16 09:59 AMNew Analyses from Phase 3 Study 009 of Translarna™ (ataluren) in Patients with Cystic Fibrosis Presented at 39th European Cystic Fibrosis Conference - [at noodls] - SOUTH PLAINFIELD, N.J., June 10, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that new analyses from the company's previous Phase 3, double-blind, placebo-controlled, 48-week ...
06/10/16 08:58 AMWhy PTC Therapeutics Jumped 10% In May - Motley Fool
06/10/16 06:15 AMBiotech Stock Mailbag: Sarepta! Always More Sarepta. And Gilead, Too -
06/09/16 08:57 AMCurrent PTC Therapeutics (NASDAQ:PTCT) PT Means Stock Is Worth Almost $40 - iStreetWire
06/09/16 08:57 AMTwo Buzzers to Observe: Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/08/16 08:59 AMPTC Therapeutics, Inc. (NASDAQ:PTCT) Insider Activities Are in the Air - iStreetWire
06/08/16 08:59 AMPTC Therapeutics Inc. (PTCT) Jumps 7.58% on June 06 - Equities.com
06/07/16 08:43 AMExelixis, Inc. (NASDAQ:EXEL) Edged Up 11.23%: PTC Therapeutics, Inc. (NASDAQ:PTCT), MeetMe, Inc. (NASDAQ ... - KC Register
06/06/16 04:41 PMETF’s with exposure to PTC Therapeutics, Inc. : June 6, 2016 -
06/06/16 09:41 AMAnalysts Rating Overview: Celldex Therapeutics, Inc. (NASDAQ:CLDX) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates
06/03/16 06:31 PMStock Review and Earnings Check on PTC Therapeutics, Inc. (NASDAQ:PTCT) - HNN
06/01/16 08:54 AMTarget Price and Stock Performance Rundown for PTC Therapeutics, Inc. (NASDAQ:PTCT) - HNN - Target Price and Stock Performance Rundown for PTC Therapeutics, Inc. (NASDAQ:PTCT)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, PTC Therapeutics, Inc. (NASDAQ ...and more »
05/29/16 10:39 AMPTC Therapeutics, Inc. (NASDAQ:PTCT) One-Year Price Target At $17.67 - Investor Newswire - PTC Therapeutics, Inc. (NASDAQ:PTCT) One-Year Price Target At $17.67Investor NewswireFirst Call has set a 52-week price target of $17.67 on PTC Therapeutics, Inc. (NASDAQ:PTCT) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-1.15 and for underway fiscal at $-4.78. This estimate for next year ...and more »
05/27/16 10:54 AMHealthcare Stocks within Traders Concentration: Medtronic plc (NYSE:MDT) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Is stories - Is storiesHealthcare Stocks within Traders Concentration: Medtronic plc (NYSE:MDT) , PTC Therapeutics, Inc. (NASDAQ:PTCT)Is storiesIn most recently trading session on 5/26/2016, PTC Therapeutics, Inc. (NASDAQ:PTCT) dropped -5.97% while traded on 1.33 million shares versus it's an average volume of 2.29 million shares. The company recorded the last trade with the price of $7.87.and more »
05/24/16 12:21 PMEarnings Trend per share for Investors: Exelixis, Inc. (NASDAQ:EXEL), PTC Therapeutics, Inc. (NASDAQ:PTCT) - Beacon Chronicle - Beacon ChronicleEarnings Trend per share for Investors: Exelixis, Inc. (NASDAQ:EXEL), PTC Therapeutics, Inc. (NASDAQ:PTCT)Beacon ChroniclePTC Therapeutics, Inc. (NASDAQ:PTCT) currently has High Price Target of $40.00. The Low and Mean Price Targets are $8.00 and $17.67 respectively. These price targets are a consensus analysis of 9 brokers. When having a look at Recommendation ...and more »
05/23/16 04:30 PMETF’s with exposure to PTC Therapeutics, Inc. : May 23, 2016 -
05/23/16 01:58 PMPTC Therapeutics, Inc. (NASDAQ:PTCT) Broker Price Targets For The Coming Week - Share Trading News - PTC Therapeutics, Inc. (NASDAQ:PTCT) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of PTC Therapeutics, Inc. (NASDAQ:PTCT). The latest reports which are currently in issue on Sunday 22nd of May state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
05/23/16 01:58 PMAnalysts Update on Stocks: Bristol-Myers Squibb Company (NYSE:BMY) , PTC Therapeutics, Inc. (NASDAQ:PTCT) - Street Updates - Analysts Update on Stocks: Bristol-Myers Squibb Company (NYSE:BMY) , PTC Therapeutics, Inc. (NASDAQ:PTCT)Street UpdatesPTC Therapeutics, Inc. (NASDAQ:PTCT) after beginning at $6.77, closed at $8.00 by building up +20.30% in recent trading session. Most recent session's volume of 3.18 million shares greater than its average volume of 2.9 million shares. The company has ...and more »
05/23/16 01:58 PMStocks in the Spotlight: PTC Therapeutics, Inc. (NASDAQ:PTCT), CIGNA Corporation (NYSE:CI), Coherus Biosciences ... - The Point Review - The Point ReviewStocks in the Spotlight: PTC Therapeutics, Inc. (NASDAQ:PTCT), CIGNA Corporation (NYSE:CI), Coherus Biosciences ...The Point ReviewShares of PTC Therapeutics, Inc. (NASDAQ:PTCT) fell -5.25% to $7.58 at 12:00 PM EDT. The stock attained the volume of 1.22 Million shares recently versus average trading volume of 2.39 Million shares. If we take a look on its volatility, 10.99 percent ...and more »
05/21/16 11:40 AM2 Surging Biotechs Attract Option Bulls Ahead of FDA Decision - And while the shares of SRPT are climbing ahead of the decision, sector peer PTC Therapeutics, Inc. (NASDAQ:PTCT)-- which makes a similar drug available in Europe, but has failed to secure U.S. approval -- appears to be getting a significant halo lift.
05/20/16 12:03 PMLatest Analyst Ratings For PTC Therapeutics, Inc. (NASDAQ:PTCT) - Share Trading News - Latest Analyst Ratings For PTC Therapeutics, Inc. (NASDAQ:PTCT)Share Trading News03/01/2016 – PTC Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 40 price target on the stock. 03/01/2016 – PTC Therapeutics, Inc. was downgraded to “neutral” by analysts at Wedbush. They now have ...Healthcare Stock gaining Momentum: PTC Therapeutics (PTCT)News Oracleall 3 news articles »
05/19/16 03:20 PMForget Sarepta Therapeutics, This DMD Stock Could Be A Better Buy -
05/19/16 11:42 AMKeep an eye on Price Trends: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Prestige Brand Holdings, Inc. (NYSE:PBH) - Street Updates - Keep an eye on Price Trends: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Prestige Brand Holdings, Inc. (NYSE:PBH)Street UpdatesOn 5/18/2016, shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) fell -2.01% in trading session and finally closed at $6.84. The company most recent volume stood at 718.21 thousand shares as compared to its average volume of 2.89 million shares. Over the ...and more »
05/18/16 12:27 PMHow Many PTC Therapeutics, Inc. (NASDAQ:PTCT)'s Analysts Are Bearish? - Wall Street Hints and News - How Many PTC Therapeutics, Inc. (NASDAQ:PTCT)'s Analysts Are Bearish?Wall Street Hints and NewsOut of 9 analysts covering PTC Therapeutics (NASDAQ:PTCT), 3 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 30% are positive. PTC Therapeutics has been the topic of 15 analyst reports since July 31, 2015 according to StockzIntelligence Inc ...Revenue Update on PTC Therapeutics(NASDAQ:PTCT)Trade Callsall 7 news articles »
05/18/16 12:27 PMPTC Therapeutics Inc. (PTCT) Jumps 6.8% on May 16 - Equities.com - PTC Therapeutics Inc. (PTCT) Jumps 6.8% on May 16Equities.comPTC Therapeutics Inc. (PTCT) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.8% to $7.22, representing a gain of $0.46 per share. Some 1.02 million shares traded hands on 5,205 trades, compared with an ...and more »
05/17/16 12:40 PMInvestors Focused Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Chiasma, Inc. (NASDAQ:CHMA) - Street Updates - Investors Focused Stocks: PTC Therapeutics, Inc. (NASDAQ:PTCT) , Chiasma, Inc. (NASDAQ:CHMA)Street UpdatesOn 5/13/2016, shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) rose +2.42% in trading session and finally closed at $6.76. The company most recent volume stood at 708.86 thousand shares as compared to its average volume of 2.88 million shares.
05/16/16 07:32 AMPTC Therapeutics Announces Winners of the Global Cystic Fibrosis Patient Group Awards - [at noodls] - SOUTH PLAINFIELD, N.J., May 16, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is pleased to announce the recipients of the Company's global STRIVE Awards (Strategies to Realize Innovation, ...
05/14/16 06:02 AMPTC Therapeutics Inc. (PTCT) Drops 8.97% on May 12 - Equities.com - PTC Therapeutics Inc. (PTCT) Drops 8.97% on May 12Equities.comPTC Therapeutics Inc. (PTCT) was one of the Russell 2000's biggest losers for Thursday May 12 as the stock slid 8.97% to $6.60, a loss of $-0.65 per share. Starting at an opening price of $7.32 a share, the stock traded between $6.54 and $7.34 over the ...and more »
05/13/16 12:04 PMPTC THERAPEUTICS, INC. Financials -
05/13/16 06:14 AMPTC Therapeutics, Inc. (NASDAQ:PTCT) Basic Consolidated EPS At $-5.0689 - RealistInvestor.com - PTC Therapeutics, Inc. (NASDAQ:PTCT) Basic Consolidated EPS At $-5.0689RealistInvestor.comThe yearly basic consolidated EPS for PTC Therapeutics, Inc. (NASDAQ:PTCT) for the period ended 2015-12-31 was $-5.0689. For the quarter ended 2015-12-31 the basic consolidated EPS was $-5.0689. Earnings per share is the portion of the firm's ...Average EPS analysis: PTC Therapeutics (NASDAQ:PTCT)News Oracleall 2 news articles »
05/12/16 02:06 PMETF’s with exposure to PTC Therapeutics, Inc. : May 12, 2016 -
05/12/16 06:24 AMStock EPS to Watch: PTC Therapeutics, Inc. (NASDAQ:PTCT) - News Oracle - Stock EPS to Watch: PTC Therapeutics, Inc. (NASDAQ:PTCT)News OracleLast Trade: The Company fell -2.20% and finished at $7.57. The daily volume was measured at 1.04 million shares. The 52-week high of the share price is $62.15 and the 52-week low is $5.27. The company has a market cap of $251.63 million. Its latest ...
05/11/16 11:13 AMPTC Therapeutics, Inc. :PTCT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/10/16 06:04 AMPTC Therapeutics Inc. (PTCT) Jumps 9.17% on May 09 - Equities.com - PTC Therapeutics Inc. (PTCT) Jumps 9.17% on May 09Equities.comPTC Therapeutics Inc. (PTCT) was among the biggest gainers on the Russell 2000 for Monday May 09 as the stock popped 9.17% to $7.74, representing a gain of $0.65 per share. Some 1.13 million shares traded hands on 6,271 trades, compared with an ...and more »
05/06/16 06:11 AMPTC Therapeutics Inc. (PTCT) Drops 9.48% on May 04 - Equities.com - PTC Therapeutics Inc. (PTCT) Drops 9.48% on May 04Equities.comPTC Therapeutics Inc. (PTCT) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 9.48% to $6.97, a loss of $-0.73 per share. Starting at an opening price of $7.66 a share, the stock traded between $6.92 and $7.79 over ...and more »
05/05/16 03:09 PMPTC THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex -
About PTC Therapeutics

PTC Therapeutics logoPTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company's lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older. Its programs include Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) in collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596). It has two compounds in clinical development within the SMA program: RG7800 and RG7916.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PTCT
  • CUSIP:
Key Metrics:
  • Previous Close: $6.66
  • 50 Day Moving Average: $7.40
  • 200 Day Moving Average: $14.69
  • P/E Ratio: N/A
  • P/E Growth: 0.14
  • Market Cap: $225.90M
  • Current Quarter EPS Consensus Estimate: $-4.93 EPS
Additional Links:
PTC Therapeutics (NASDAQ:PTCT) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha